Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges
出版年份 2018 全文链接
标题
Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges
作者
关键词
-
出版物
Oxidative Medicine and Cellular Longevity
Volume 2018, Issue -, Pages 1-17
出版商
Hindawi Limited
发表日期
2018-10-30
DOI
10.1155/2018/3693625
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML
- (2018) Lauren Herschbein et al. BLOOD REVIEWS
- Drug discovery targeting the mTOR pathway
- (2018) Alberto M. Martelli et al. CLINICAL SCIENCE
- Genetics of Autosomal Recessive Polycystic Kidney Disease and Its Differential Diagnoses
- (2018) Carsten Bergmann Frontiers in Pediatrics
- Recent developments in small molecule therapies for renal cell carcinoma
- (2017) Minsoo Song EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Localization of mTORC2 activity inside cells
- (2017) Michael Ebner et al. JOURNAL OF CELL BIOLOGY
- Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis
- (2017) Ao Li et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases
- (2017) Emilie Cornec-Le Gall et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex
- (2017) Filipe Palavra et al. Oxidative Medicine and Cellular Longevity
- Twenty-five years of mTOR: Uncovering the link from nutrients to growth
- (2017) David M. Sabatini PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Best Abstract Challenge
- (2017) TRANSPLANT INTERNATIONAL
- The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent
- (2017) Zuquan Xiong et al. Oncotarget
- The Genetic and Cellular Basis of Autosomal Dominant Polycystic Kidney Disease—A Primer for Clinicians
- (2017) Adrián Cordido et al. Frontiers in Pediatrics
- High-Throughput Phenotypic Screening of Kinase Inhibitors to Identify Drug Targets for Polycystic Kidney Disease
- (2017) Tijmen H. Booij et al. SLAS Discovery
- Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
- (2016) Timon Vandamme et al. BRITISH JOURNAL OF CANCER
- A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer
- (2016) Thomas Powles et al. EUROPEAN UROLOGY
- Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
- (2016) David Cella et al. LANCET ONCOLOGY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- (2016) Vanessa S. Rodrik-Outmezguine et al. NATURE
- Roles of mTOR complexes in the kidney: implications for renal disease and transplantation
- (2016) Daniel Fantus et al. Nature Reviews Nephrology
- Inhibition of the Mechanistic Target of Rapamycin (mTOR)–Rapamycin and Beyond
- (2016) Dudley W. Lamming Cold Spring Harbor Perspectives in Medicine
- Potential therapeutic effects of mTOR inhibition in atherosclerosis
- (2015) Ammar Kurdi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders
- (2015) Kenneth Maiese BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma
- (2015) Bing Zheng et al. CANCER LETTERS
- Molecular Basis of the Rapamycin Insensitivity of Target Of Rapamycin Complex 2
- (2015) Christl Gaubitz et al. MOLECULAR CELL
- Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex
- (2015) Jeffrey P. MacKeigan et al. NEURO-ONCOLOGY
- Molecular Pathways and Therapies in Autosomal-Dominant Polycystic Kidney Disease
- (2015) Takamitsu Saigusa et al. PHYSIOLOGY
- Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors
- (2015) Fangbin Han et al. ACS Medicinal Chemistry Letters
- The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges
- (2015) Bianca Cheaib et al. Chinese Journal of Cancer
- Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
- (2015) Burhan Hassan et al. Oncotarget
- Five-Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study
- (2014) K. Budde et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Cyclosporine A enhances gluconeogenesis while sirolimus impairs insulin signaling in peripheral tissues after 3 weeks of treatment
- (2014) P.C. Lopes et al. BIOCHEMICAL PHARMACOLOGY
- Molecular mechanisms underlying the effects of cyclosporin A and sirolimus on glucose and lipid metabolism in liver, skeletal muscle and adipose tissue in an in vivo rat model
- (2014) A. Fuhrmann et al. BIOCHEMICAL PHARMACOLOGY
- Rapamycin preventsN-methyl-D-aspartate-induced retinal damage through an ERK-dependent mechanism in rats
- (2014) Atsuko Ichikawa et al. JOURNAL OF NEUROSCIENCE RESEARCH
- Short and long term in vivo effects of Cyclosporine A and Sirolimus on genes and proteins involved in lipid metabolism in Wistar rats
- (2014) Patrícia C. Lopes et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- mTOR controls kidney epithelia in health and disease
- (2014) F. Grahammer et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease
- (2014) K. Ravichandran et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Regulation of mTORC1 by amino acids
- (2014) Liron Bar-Peled et al. TRENDS IN CELL BIOLOGY
- Conversion to Sirolimus Ameliorates Cyclosporine-Induced Nephropathy in the Rat: Focus on Serum, Urine, Gene, and Protein Renal Expression Biomarkers
- (2014) José Sereno et al. Biomed Research International
- Podocyte Regeneration
- (2013) Florian Grahammer et al. AMERICAN JOURNAL OF PATHOLOGY
- Differentiating mTOR inhibitors in renal cell carcinoma
- (2013) Sumanta K. Pal et al. CANCER TREATMENT REVIEWS
- Metabolic complications with the use of mTOR inhibitors for cancer therapy
- (2013) Shanthi Sivendran et al. CANCER TREATMENT REVIEWS
- ERK1/2-dependent activation of mTOR/mTORC1/p70S6K regulates thrombin-induced RPE cell proliferation
- (2013) Alejandro Parrales et al. CELLULAR SIGNALLING
- AKT2 is essential to maintain podocyte viability and function during chronic kidney disease
- (2013) Guillaume Canaud et al. NATURE MEDICINE
- Effects of Cyclosporine and Sirolimus on Insulin-Stimulated Glucose Transport and Glucose Tolerance in a Rat Model
- (2013) P. Lopes et al. TRANSPLANTATION PROCEEDINGS
- Serum and Renal Tissue Markers of Nephropathy in Rats Under Immunosuppressive Therapy: Cyclosporine Versus Sirolimus
- (2013) J. Sereno et al. TRANSPLANTATION PROCEEDINGS
- Autosomal dominant polycystic kidney disease in a family with mosaicism and hypomorphic allele
- (2013) Jana Reiterová et al. BMC Nephrology
- Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation
- (2013) V. Ram Peddi et al. Transplantation Reviews
- Efficacy and Safety of mTOR Inhibitor Therapy in Patients With Early-Stage Autosomal Dominant Polycystic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials
- (2012) Qiang He et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- Five-Year Results of a Randomized Trial Comparing De Novo Sirolimus and Cyclosporine in Renal Transplantation: The Spiesser Study
- (2012) Y. Lebranchu et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Donor-Specific HLA Antibodies in a Cohort Comparing Everolimus With Cyclosporine After Kidney Transplantation
- (2012) L. Liefeldt et al. AMERICAN JOURNAL OF TRANSPLANTATION
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Mammalian target of rapamycin signaling in the podocyte
- (2012) Ken Inoki et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Dose-Dependent Effects of Sirolimus on mTOR Signaling and Polycystic Kidney Disease
- (2012) Z. Novalic et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Combined therapeutic application of mTOR inhibitor and vitamin D3 for inflammatory bone destruction of rheumatoid arthritis
- (2012) Tae-Hwan Kim et al. MEDICAL HYPOTHESES
- mTOR inhibition with rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes
- (2012) Maria J. Pereira et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- The immunosuppressive agents rapamycin, cyclosporin A and tacrolimus increase lipolysis, inhibit lipid storage and alter expression of genes involved in lipid metabolism in human adipose tissue
- (2012) Maria J. Pereira et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study
- (2012) G. Stallone et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Sirolimus Induced Phosphaturia is Not Caused by Inhibition of Renal Apical Sodium Phosphate Cotransporters
- (2012) Maria Haller et al. PLoS One
- Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
- (2012) D. W. Lamming et al. SCIENCE
- A Dynamic Network Model of mTOR Signaling Reveals TSC-Independent mTORC2 Regulation
- (2012) P. Dalle Pezze et al. Science Signaling
- Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation
- (2012) Robert M Langer et al. TRANSPLANT INTERNATIONAL
- The ORION Study: Comparison of Two Sirolimus-Based Regimens versus Tacrolimus and Mycophenolate Mofetil in Renal Allograft Recipients
- (2011) S. M. Flechner et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody-Mediated Rejection and Nonadherence
- (2011) J. Sellarés et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney
- (2011) Laura R. Pearce et al. BIOCHEMICAL JOURNAL
- Activation of mTORC2 by Association with the Ribosome
- (2011) Vittoria Zinzalla et al. CELL
- mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway
- (2011) Timothy R. Peterson et al. CELL
- mSIN1 Protein Mediates SGK1 Protein Interaction with mTORC2 Protein Complex and Is Required for Selective Activation of the Epithelial Sodium Channel
- (2011) Ming Lu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
- (2011) Markus Gödel et al. JOURNAL OF CLINICAL INVESTIGATION
- mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice
- (2011) Ken Inoki et al. JOURNAL OF CLINICAL INVESTIGATION
- Increased Tubular Proliferation as an Adaptive Response to Glomerular Albuminuria
- (2011) J.-K. Guo et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer
- (2011) Aymen A Elfiky et al. Journal of Translational Medicine
- Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial
- (2011) Klemens Budde et al. LANCET
- Why kidneys fail in autosomal dominant polycystic kidney disease
- (2011) Jared J. Grantham et al. Nature Reviews Nephrology
- mTOR signaling in polycystic kidney disease
- (2011) Oxana Ibraghimov-Beskrovnaya et al. TRENDS IN MOLECULAR MEDICINE
- mTOR Signaling
- (2011) M. Laplante et al. Cold Spring Harbor Perspectives in Biology
- Therapeutic mTOR Inhibition in Autosomal Dominant Polycystic Kidney Disease: What Is the Appropriate Serum Level?
- (2010) G. Canaud et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Epidermal growth factor-mediated proliferation and sodium transport in normal and PKD epithelial cells
- (2010) Nadezhda N. Zheleznova et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Mycophenolate mofetil versus Rapamycin in Han: SPRD rats with Polycystic Kidney Disease
- (2010) TONG ZHANG et al. BIOLOGICAL RESEARCH
- Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
- (2010) V. P. Houde et al. DIABETES
- Sirolimus Therapy to Halt the Progression of ADPKD
- (2010) N. Perico et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease
- (2010) Iram Zafar et al. KIDNEY INTERNATIONAL
- mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression
- (2010) Tobias B. Huber et al. KIDNEY INTERNATIONAL
- Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial
- (2010) Matthew R. Weir et al. KIDNEY INTERNATIONAL
- Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies
- (2010) N Chapuis et al. LEUKEMIA
- Structure of the Human mTOR Complex I and Its Implications for Rapamycin Inhibition
- (2010) Calvin K. Yip et al. MOLECULAR CELL
- mTOR: from growth signal integration to cancer, diabetes and ageing
- (2010) Roberto Zoncu et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats
- (2010) C. Renken et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease
- (2010) Andreas L. Serra et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
- (2010) Gerd Walz et al. NEW ENGLAND JOURNAL OF MEDICINE
- mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
- (2010) R. J. O. Dowling et al. SCIENCE
- Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study
- (2009) Y. Lebranchu et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia
- (2009) J. Tamburini et al. BLOOD
- Rictor/TORC2 regulates fat metabolism, feeding, growth, and life span in Caenorhabditis elegans
- (2009) A. A. Soukas et al. GENES & DEVELOPMENT
- Significance and Management of Proteinuria in Kidney Transplant Recipients
- (2009) H. Amer et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The Role of the Mammalian Target Of Rapamycin (mTOR) in Renal Disease
- (2009) W. Lieberthal et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis
- (2009) Vincent H. Gattone et al. KIDNEY INTERNATIONAL
- Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage?
- (2009) J. Torras et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Insulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 Pathway
- (2009) Hui H. Zhang et al. PLoS One
- Long-Term Treatment of Sirolimus but Not Cyclosporine Ameliorates Diabetic Nephropathy in the Rat
- (2009) Sandra Wittmann et al. TRANSPLANTATION
- Hypertension Induced by Immunosuppressive Drugs: A Comparative Analysis Between Sirolimus and Cyclosporine
- (2009) F. Reis et al. TRANSPLANTATION PROCEEDINGS
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- Sirolimus Reduces Polycystic Liver Volume in ADPKD Patients
- (2008) Q. Qian et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started